Reg-D Private Placement: Accredited Investor Offering

Step 1:

Head to Our Form and fill out the subscription form

Investor offering form

Step 2:

Download the W-9 IRS form, directly from Here fill it out and email it back to us at investors@medlab.group

W-9 IRS PDF

Step 3:

Finally, wire the specified investment amount to the bank details below:

WIRING INSTRUCTIONS FOR:
BRINEN & ASSOCIATES, LLC
330 SEVENTH AVENUE, SUITE 50, NEW YORK, NEW YORK 10001
TEL: (212)-330-8151 FAX: (212)-227-0201

CONTACT PERSON:
JOSHUA D. BRINEN, ESQ.

NAME OF ACCOUNT:
IOLA – Brinen & Associates, LLC
Attorney Trust Account

ACCOUNT NUMBER:
00483002939026

NAME OF BANK:
BANK OF AMERICA
261 BROADWAY, NEW YORK, NEW YORK 10007
(212)-271-7476

ROUTING NO.: 026009593
SWIFT CODE: BOFAUS3N

Please note that the funds transfer should match the calculation column of your subscription and application form.

Investor FAQ

  • Common Stock, priced at $5 per share

  • The purchase price is $5 per share, and the minimum parcel is size, is 1,000 shares. This means the minimum investment id $5,000.

  • $5,000,000 to $10,000,000

  • No, this is a private placement to accredited investors only: Reg-D offering. The company has an underwirtten agreement for an IPO first half of 2026. The IPO will be a public offering.

  • Accredited investor under the Reg-D offering will be able to acquire common stock at a 50% discount to the future IPO price.

  • ItThe company is focused on:

    • Cancer induced pain, with potential extensions into broader pain topics

    • Chemotherapy indiced nasuea and vomiting

    • Muscle loss and recovery

    • cellulr health, and communication

    the above covers significant global addressable markets with vast commercialisation potential.

  • The company has a portfolio of approved nutraceuticals, to which the company intendes to licence and not self promote, these can be viewed here.

  • We have partnered with EquiDeFi, an ethical and known platform to facility convenience, documentation and stock transfer.

  • Simply email us at investors@medlab.group cite your initial questions and we will schedule at time discuss further with relevant people.